Fluorinated phenylamino compounds and pharmaceutical compositions
AssigneeSpringworks Therapeutics, Inc.
InventorsKristin Patterson, Piero L Ruggiero
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to fluorinated phenylamino compounds, their pharmaceutical compositions, and methods for treating one or more tumors or cancers selected from the group consisting of plexiform neurofibromas (PN), plexiform neurofibromas associated with neurofibromatosis type 1 (NF1-PN), cutaneous neurofibromas (cNF), pancreatic ductal adenocarcinoma (PDAC), high grade glioma (HGG), low grade ovarian cancer, tuberous sclerosis (TSC), Langerhans cell histiocytosis (LCH), brain cancer, and a cancer that has metastasized to a patient's brain, comprising administering to a patient in need thereof, those pharmaceutical compositions.
Claims18
A compound which is selected from the group consisting of:
- and pharmaceutically acceptable salts thereof.
A pharmaceutical composition comprising (a) a compound selected from the group consisting of:
- 3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzoic acid 2,3-dihydroxy-propyl ester;
- 3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzoic acid 3-[1-carboxy-meth-(E)-ylideneaminooxy]-2-hydroxy-propyl ester;
- 3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzoic acid 2-hydroxy-3-methyleneaminooxy-propyl ester;
- and
- pharmaceutically acceptable salts thereof;
- and
- (b) a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.